🟠 The RIDGELINE Trial (VX21-121-105) evaluated Alyftrek (vanzacaftor-tezacaftor-deutivacaftor) over 24 weeks in 78 #children with cystic fibrosis (#CF) aged 6–11 years.
#CRISPR #biotech $VRTX $NTLA $PRME $EDIT @FDA